Amicus Therapeutics, Inc.FOLDNASDAQ
Loading
R&D Expenses Over TimeContracting
Percentile Rank50
3Y CAGR-21.1%
5Y CAGR-15.1%
Year-over-Year Change
Research and development spending
3Y CAGR
-21.1%/yr
vs +0.5%/yr prior
5Y CAGR
-15.1%/yr
Recent deceleration
Acceleration
-21.6pp
Decelerating
Percentile
P50
Within normal range
vs 5Y Ago
0.4x
Contraction
Streak
1 yr
Consecutive growthContracting
| Period | Value | YoY Change |
|---|---|---|
| 2025 | $135.84M | +24.2% |
| 2024 | $109.36M | -28.2% |
| 2023 | $152.38M | -44.9% |
| 2022 | $276.68M | +1.7% |
| 2021 | $272.05M | -11.8% |
| 2020 | $308.44M | +7.7% |
| 2019 | $286.38M | +5.7% |
| 2018 | $270.90M | +81.4% |
| 2017 | $149.31M | +42.5% |
| 2016 | $104.79M | - |